Upperton Strengthens Capabilities with Installation of Gerteis Roller Compactor
Upperton strengthens capabilities with installation of Gerteis roller compactor at Nottingham gmp manufacturing facility.
Upperton announces expansion into sterile drug manufacturing with new £5million GMP facility
Upperton Pharma Solutions has announced a £5million investment to expand operations into small-scale sterile fill-finish.
Continued Growth During 2023 – Milestones and Achievements
What a year 2023 has been. A year of remarkable growth and achievements, award-winning, and new standards in gmp manufacturing facilities.
Upperton Pharma Solutions Win’s Prestigious King’s Award for Enterprise: International Trade 2023
Upperton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO) specialising in the development and manufacture of innovative drug formulations, has been announced as a winner of the King’s Award for Enterprise, International Trade. The King’s Award for Enterprise is a highly prestigious award for UK businesses who have demonstrated outstanding innovation in their industry. […]
Upperton completes build of new £15m development and GMP manufacturing facility
Leading UK contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has completed the build of its new development and GMP manufacturing headquarters in Nottingham, UK. Situated less than two miles from Upperton’s current HQ, the facility ‘Trent Gateway’ houses ten new GMP manufacturing suites, quality control laboratories and formulation development with pilot plant capabilities. […]
Nasal Inhalation Delivery – An Introduction Guide
An introduction to nasal delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route. Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. […]
Upperton Increases Oral Dosage Form Capabilities at its Nottingham HQ
20th April 2023 : Press Release Nottingham, UK, 20th April: Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced in January this year, the state-of-the-art facility has benefited from a […]
Nasally Delivered Dry Powder Dosage Forms: Particle Size Analysis
Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route.Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. for fast […]
What’s New In 2023: ExcitingPlans For Upperton Pharma Solutions
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and […]
Upperton’s new Nottingham facility
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the […]